Form 4: Keros Therapeutics Director Sells Shares

Director Nima Farzan sold 2,625 shares of Keros Therapeutics common stock via a pre-arranged 10b5-1 trading plan.

Summary

• Director Nima Farzan sold 2,625 shares of Keros Therapeutics (KROS) common stock.
• The sale occurred on June 4, 2026, at a weighted average price of $10.73 per share.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on December 5, 2025.
• Following the transaction, the reporting person retains beneficial ownership of 9,767 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed via a pre-planned 10b5-1 program, which is a standard and non-discretionary financial activity.

Positives

• The sale was conducted under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell shares without concerns regarding non-public information.

Negatives

• The transaction represents a reduction in the director's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation or future prospects.

Future Outlook

No forward-looking guidance or operational outlook was provided in this filing.

Industry Context

StockSavvy.ai notes that routine insider selling under 10b5-1 plans is common in the biotechnology sector and typically does not reflect a change in company fundamentals or strategic direction.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for corporate insiders to manage personal liquidity while maintaining regulatory compliance.

Stakeholder Impact

• Minimal impact on shareholders as the sale was pre-planned and represents a small portion of the director's holdings.

Key Dates

Keywords

Keros Therapeutics, KROS, Insider Trading, Form 4, Nima Farzan, Biotech